Back to results
US 2014/0155493 A1Published application
Bis-aromatic anticancer agents
AssigneeThe UAB Research Foundation
InventorAhmad Safavy
Life of this patent
Estimating the term…
Abstract
Treatment of cancer includes administering a compound of formula (I) to a subject. In particular, treatment of colorectal cancer is described.
Claims13
1-24. (canceled)
A method of treating cancer in a subject, the method comprising administering to the subject an effective amount of a compound according to formula (II):
- wherein:
- X is selected from:
- S;
- S═O;
- and SO2;
- each Z is independently selected from H;
- C1-10 alkyl;
- OR1;
- halo;
- ═O;
- NR1R2;
- NO2;
- CN;
- SR1;
- SO2;
- COOR1;
- C5-12 cycloalkyl;
- C5-12 heterocycloalkyl;
- C5-12 aryl;
- and C5-12 heteroaryl;
- wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl may be substituted or unsubstituted;
- each W is independently selected from:
- C1-10 alkyl;
- OR1;
- halo;
- NR1R2;
- NO2;
- CN;
- SR1;
- SO2;
- COOR1;
- C5-12 cycloalkyl;
- C5-12 heterocycloalkyl;
- C5-12 aryl;
- and C5-12 heteroaryl;
- wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl may be substituted or unsubstituted;
- each R1 and R2 is independently H or C1-10 substituted or unsubstituted alkyl;
- m is independently an integer from 0 to 10;
- n is independently an integer from 0 to 10;
- and
- each p is independently an integer from 0 to 5;
- or
- a pharmaceutically acceptable salt form thereof.
40 more elements
A method of promoting cell death in a cell, the method comprising contacting the cell with a therapeutically effective amount of a compound of formula (II):
- wherein:
- X is selected from:
- S;
- S═O;
- and SO2;
- each Z is independently selected from H;
- C1-10 alkyl;
- OR1;
- halo;
- ═O;
- NR1R2;
- NO2;
- CN;
- SR1;
- SO2;
- COOR1;
- C5-12 cycloalkyl;
- C5-12 heterocycloalkyl;
- C5-12 aryl;
- and C5-12 heteroaryl;
- wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl may be substituted or unsubstituted;
- each W is independently selected from:
- C1-10 alkyl;
- OR1;
- halo;
- NR1R2;
- NO2;
- CN;
- SR1;
- SO2;
- COOR1;
- C5-12 cycloalkyl;
- C5-12 heterocycloalkyl;
- C5-12 aryl;
- and C5-12 heteroaryl;
- wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl may be substituted or unsubstituted;
- each R1 and R2 is independently H or C1-10 substituted or unsubstituted alkyl;
- m is independently an integer from 0 to 10;
- n is independently an integer from 0 to 10;
- and
- each p is independently an integer from 0 to 5;
- or
- a pharmaceutically acceptable salt form thereof.
40 more elements
A pharmaceutical composition comprising one or more of a pharmaceutically acceptable carrier, excipient, diluent, or adjuvant;
- and a compound according to formula (II):
- wherein:
- X is selected from:
- S;
- S═O;
- and SO2;
- each Z is independently selected from H;
- C1-10 alkyl;
- OR1;
- halo;
- ═O;
- NR1R2;
- NO2;
- CN;
- SR1;
- SO2;
- COOR1;
- C5-12 cycloalkyl;
- C5-12 heterocycloalkyl;
- C5-12 aryl;
- and C5-12 heteroaryl;
- wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl may be substituted or unsubstituted;
- each W is independently selected from:
- C1-10 alkyl;
- OR1;
- halo;
- NR1R2;
- NO2;
- CN;
- SR1;
- SO2;
- COOR1;
- C5-12 cycloalkyl;
- C5-12 heterocycloalkyl;
- C5-12 aryl;
- and C5-12 heteroaryl;
- wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl may be substituted or unsubstituted;
- each R1 and R2 is independently H or C1-10 substituted or unsubstituted alkyl;
- m is independently an integer from 0 to 10;
- n is independently an integer from 0 to 10;
- and
- each p is independently an integer from 0 to 5;
- or
- a pharmaceutically acceptable salt form thereof.
41 more elements
Dependencies are inferred from the claim text.